APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

NCT04657861 | Recruiting Early Phase 1 DMC

• 1 other identifier: APRIL-001
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma

Conditions

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory

Keywords

Multiple Myeloma; CAR T-cell therapy; BCMA/TACI positive

Outcome Measures

Primary Outcomes (2)

• Dose-limiting toxicity (DLT)

  Adverse events assessed according to NCI-CTCAE v5.0 criteria

  Baseline up to 28 days after APRIL targeted CAR T-cells infusion

• Incidence of treatment-emergent adverse events (TEAEs)

  Incidence of treatment-emergent adverse events \[Safety and Tolerability\]

  Time Frame: Up to 2 years after APRIL targeted CAR T-cells infusion

Secondary Outcomes (7)

• Multiple Myeloma (MM), Overall response rate (ORR)

  At Month 1, 3, 6, 12, 18 and 24

• MM, Overall survival (OS)

  Up to 2 years after APRIL CAR-T cells infusion

• MM, Event-free survival (EFS)

  Up to 2 years after APRIL CAR-T cells infusion

• Quality of life including sports activity

  At Baseline, Month 1, 3, 6, 9 and 12

• Activities of Daily Living (ADL) score

  At Baseline, Month 1, 3, 6, 9 and 12

Study Arms (1)

Administration of APRIL CAR T-cells

EXPERIMENTAL

Each subject receive APRIL CAR T-cells by intravenous infusion

Drug: APRIL CAR-T cells

Interventions

APRIL CAR-T cells DRUG

Each subject receive APRIL CAR T-cells by intravenous infusion

Also known as: APRIL CAR-T cells injection

Administration of APRIL CAR T-cells

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically confirmed diagnosis of BCMA/TACI+ multiple myeloma (MM)：
• Patients with MM relapsed after BCMA CAR-T therapy; Or MM with positive BCMA/TACI expression;
• Relapsed after hematopoietic stem cell transplantation;
• Cases with recurrent positive minimal residual disease;
• Extramedullary leision which is hard to be eradicated by chemotherapy or radiotherapy.
• Male or female aged 18-75 years;
• Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L;
• Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;
• No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;
• Estimated survival time ≥ 3 months;
• ECOG performance status 0 to 2;
• Patients or their legal guardians volunteer to participate in the studyand sign the informed consent.

You may not qualify if:

• History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases;
• Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
• Pregnant (or lactating) women;
• Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);
• Active infection of hepatitis B virus or hepatitis C virus;
• Concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving in haled steroids;
• Previously treated with any CAR-T cell product or other genetically modified T cell therapies;
• Creatinine\>2.5mg/dl, or ALT / AST \> 3 times of normal amounts, or bilirubin\>2.0 mg/dl;
• Other uncontrolled diseases that were not suitable for this trial;
• Patients with HIV infection;
• Any situations that the investigator believes may increase the risk of patients or interfere with the results of study

Sponsors & Collaborators

• Zhejiang University: lead
• Yake Biotechnology Ltd.: collaborator

Study Sites (1)

The First Affiliated Hospital，College of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310003, China

RECRUITING

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Central Study Contacts

He Huang, PhD

CONTACT

86-13605714822; hehuangyu@126.com

Yongxian Hu, PhD

CONTACT

86-15957162012; huyongxian2000@aliyun.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: October 22, 2020
• First Posted: December 8, 2020
• Study Start: May 3, 2022
• Primary Completion: August 20, 2024
• Study Completion (Estimated): August 20, 2027
• Last Updated: May 9, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)